Drug Profile

Dexamethasone sodium phosphate - AVM Biotechnology

Alternative Names: AVM-0703; Supra-Pharmacologic Dexamethasone sodium phosphate - AVM Biotechnology

Latest Information Update: 28 Oct 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator AVM Biotechnology
Class Anti-inflammatories; Antiallergics; Antiemetics; Antihyperglycaemics; Antineoplastics; Antirheumatics; Eye disorder therapies; Fluorinated steroids; Glucocorticoids; Ketones; Non-opioid analgesics; Phosphates; Pregnadienetriols; Small molecules; Sodium compounds; Vestibular disorder therapies
Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants; Natural killer T cell stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Phase I/II Lymphoma
Preclinical Type 1 diabetes mellitus
No development reported Adult respiratory distress syndrome; B-cell lymphoma; Burkitt's lymphoma; Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Lymphoid leukaemia; Mantle-cell lymphoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; T-cell leukaemia; T-cell lymphoma

28 Oct 2024 No recent reports of development identified for preclinical development in Adult-respiratory-distress-syndrome in USA (IV)
31 May 2024 Pharmacodynamics data from a preclinical trial in Diffused large B-cell lymphoma presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
31 May 2024 Efficacy and adverse event data from a phase I/II trial in Lymphoma presented at the 60^th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com